Navigation Links
Cancer and psoriasis triggered by mast cells

proteins that regulate the recruitment of inflammatory cells. Since it is already known that levels of CD30 are higher in people with psoriasis or atopical eczema and with Hodgkins lymphoma, the results can explain how the mast cells are activated and how they aggravate inflammation in these diseases.

Source-Eurekalert
'"/>




Page: 1 2

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
Other Medicine News:Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 2Health News:Growth hormone is used to treat twice as many short boys than girls in the US and Asia 3Health News:Anthem Blue Cross and Blue Shield Celebrates Local Moms-to-Be at Community Baby Shower 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 2Health News:The Best Things in Life Are ... In Better Health & Living(R), A Free, Premium Magazine Launching April 26 in the Twin Cities 3Health News:U-M study: Work hassles hamper sleep 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 2Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 3Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 4Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 5Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 6Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 7Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 8Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 9Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 10Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 11Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 12Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 13Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 14Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 15Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 16Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 17Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 18Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 19Health News:Southwest Bancorp Reports First Quarter 2008 Earnings per Share of $0.36 20Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 2Health News:Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data 3
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3AMD LASERS Announces Partnerships With Three Industry Leading Companies 5686 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 2Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 3Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 1Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 2
Other Medicine Technology:New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7